These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8532725)

  • 1. Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment.
    McClain RM
    Prog Clin Biol Res; 1995; 391():325-36. PubMed ID: 8532725
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver tumor promoters and other mouse liver carcinogens.
    Ward JM; Diwan BA; Lubet RA; Henneman JR; Devor DE
    Prog Clin Biol Res; 1990; 331():85-108. PubMed ID: 2179967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver tumour promotion by phenobarbital: comparison of rat and human studies.
    McLean AE; Driver HE; Sutherland IA
    Prog Clin Biol Res; 1992; 374():251-9. PubMed ID: 1320274
    [No Abstract]   [Full Text] [Related]  

  • 4. Promotion of hepatocarcinogenesis in humans and animal models.
    Köhle C; Schwarz M; Bock KW
    Arch Toxicol; 2008 Sep; 82(9):623-31. PubMed ID: 18204979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The species specificity of dieldrin- or phenobarbital- induced hepatocarcinogenesis: case studies with implications for human health risk assessment.
    Stevenson DE; Walborg EF; Klaunig JE
    Prog Clin Biol Res; 1995; 391():337-45. PubMed ID: 8532726
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in connexin32-null mice.
    Moennikes O; Buchmann A; Romualdi A; Ott T; Werringloer J; Willecke K; Schwarz M
    Cancer Res; 2000 Sep; 60(18):5087-91. PubMed ID: 11016633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse liver tumors and microsomal enzyme-inducing drugs: experimental and clinical perspectives with phenobarbital.
    McClain RM
    Prog Clin Biol Res; 1990; 331():345-65. PubMed ID: 2156272
    [No Abstract]   [Full Text] [Related]  

  • 8. Human cancer risk estimates are reduced when based on relative risk for common rodent tumors.
    Gaylor DW; Kodell RL; Chen JJ
    Regul Toxicol Pharmacol; 1999 Dec; 30(3):283-4. PubMed ID: 10620477
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of mouse liver tumor data in risk assessments performed by the U.S. Environmental Protection Agency.
    Beal DD
    Prog Clin Biol Res; 1990; 331():5-18. PubMed ID: 2179964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of carcinogenic risk based on mode of drug action.
    Fujii T
    J Toxicol Sci; 1995 Sep; 20(4):459-61. PubMed ID: 8531241
    [No Abstract]   [Full Text] [Related]  

  • 11. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion.
    Whysner J; Ross PM; Williams GM
    Pharmacol Ther; 1996; 71(1-2):153-91. PubMed ID: 8910954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital.
    Loeppen S; Schneider D; Gaunitz F; Gebhardt R; Kurek R; Buchmann A; Schwarz M
    Cancer Res; 2002 Oct; 62(20):5685-8. PubMed ID: 12384525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenobarbital and related compounds: approaches to interspecies extrapolation.
    Rice JM; Diwan BA; Ward JM; Nims RW; Lubet RA
    Prog Clin Biol Res; 1992; 374():231-49. PubMed ID: 1620706
    [No Abstract]   [Full Text] [Related]  

  • 14. Chloroform mode of action: implications for cancer risk assessment.
    Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver tumor promotion: a process of natural selection.
    Jirtle RL
    Prog Clin Biol Res; 1995; 391():149-59. PubMed ID: 8532713
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice.
    Mirsalis JC; Shimon JA; Johnson A; Fairchild D; Kanazawa N; Nguyen T; de Boer J; Glickman B; Winegar RA
    Environ Mol Mutagen; 2005; 45(1):17-35. PubMed ID: 15605353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dieldrin and phenobarbital on preneoplastic hepatic lesion growth in male F344 rat and B6C3F1 mouse.
    Kolaja KL; Stevenson DE; Walborg EF; Klaunig JE
    Prog Clin Biol Res; 1995; 391():409-23. PubMed ID: 8532733
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors.
    Aydinlik H; Nguyen TD; Moennikes O; Buchmann A; Schwarz M
    Oncogene; 2001 Nov; 20(53):7812-6. PubMed ID: 11753661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological classification of mouse liver tumors based on biological characteristics.
    Becker FF
    Cancer Res; 1982 Oct; 42(10):3918-23. PubMed ID: 7104991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.